Edition:
United States

Strongbridge Biopharma plc (SBBP.OQ)

SBBP.OQ on NASDAQ Stock Exchange Global Select Market

5.15USD
17 Aug 2018
Change (% chg)

$-0.25 (-4.63%)
Prev Close
$5.40
Open
$5.35
Day's High
$5.40
Day's Low
$5.15
Volume
68,108
Avg. Vol
97,098
52-wk High
$9.25
52-wk Low
$4.32

Latest Key Developments (Source: Significant Developments)

Strongbridge Biopharma Plc Files For Resale Of Up To 26.5 Mln Ordinary Shares By The Selling Shareholders
Monday, 12 Mar 2018 08:38am EDT 

March 12 (Reuters) - Strongbridge Biopharma Plc ::STRONGBRIDGE BIOPHARMA PLC FILES FOR RESALE OF UP TO 26.5 MILLION ORDINARY SHARES BY THE SELLING SHAREHOLDERS - SEC FILING.  Full Article

Strongbridge Biopharma Reports Q4 GAAP Loss Per Share $0.47
Monday, 12 Mar 2018 07:30am EDT 

March 12 (Reuters) - Strongbridge Biopharma Plc ::REPORTS FULL-YEAR 2017 FINANCIAL RESULTS.Q4 NON-GAAP LOSS PER SHARE $0.31.Q4 GAAP LOSS PER SHARE $0.47.Q4 EARNINGS PER SHARE VIEW $-0.32 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE $16 MILLION TO $19 MILLION.‍ MACRILEN PRODUCT LAUNCH ON TRACK FOR MID-2018​.QTRLY ‍NET REVENUES OF $3.0 MILLION​.  Full Article

Strongbridge Gets Letters From Offices Of U.S. Senators Requesting Information On Marketing & Sales Of Keveyis
Thursday, 21 Dec 2017 07:49am EST 

Dec 21 (Reuters) - Strongbridge Biopharma Plc ::STRONGBRIDGE BIOPHARMA - ON DEC 19, RECEIVED LETTERS FROM OFFICES OF U.S. SENATORS THAT REQUEST INFORMATION RELATING TO MARKETING & SALES OF KEVEYIS.STRONGBRIDGE BIOPHARMA - LETTERS REQUEST INFORMATION PRINCIPALLY RELATING TO THE PRICING OF KEVEYIS, AMONG OTHER THINGS - SEC FILING.STRONGBRIDGE BIOPHARMA - CO IN THE PROCESS OF RESPONDING TO THE LETTERS.  Full Article

Strongbridge Biopharma Q3 loss per share $0.98
Tuesday, 14 Nov 2017 07:30am EST 

Nov 14 (Reuters) - Strongbridge Biopharma Plc :Strongbridge Biopharma Plc provides corporate update and reports third quarter 2017 financial results.Q3 non-GAAP loss per share $0.35.Q3 GAAP loss per share $0.98.Q3 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.Strongbridge Biopharma Plc- ‍Recorlev (levoketoconazole) phase 3 top-line results remain on track with SONICS in Q2 2018 and LOGICS in Q4 2018​.Strongbridge Biopharma Plc- existing cash resources at Sept 30, net proceeds from Oct offering provides sufficient cash under current operating plan​.Strongbridge Biopharma Plc- ‍had pro forma cash and cash equivalents of $67.8 million as of September 30, 2017​.Strongbridge Biopharma Plc - qtrly total revenues $‍2.5 million​.  Full Article

Strongbridge Biopharma Plc announces proposed public offering of ordinary shares
Tuesday, 3 Oct 2017 04:02pm EDT 

Oct 3 (Reuters) - Strongbridge Biopharma Plc :Strongbridge Biopharma Plc announces proposed public offering of ordinary shares.Strongbridge Biopharma Plc - ‍intends to offer and sell its ordinary shares in an underwritten public offering​.Strongbridge - to use proceeds for investment in expanded commercial infrastructure for KEVEYIS, continued development of RECORLEV and veldoreotide.  Full Article

Armistice Capital Llc reports 5.1 percent passive stake in Strongbridge Biopharma
Friday, 22 Sep 2017 05:36pm EDT 

Sept 22 (Reuters) - Strongbridge Biopharma Plc :Armistice Capital Llc reports 5.1 percent passive stake in Strongbridge Biopharma Plc as of Sept 12, 2017 - SEC filing.  Full Article

Strongbridge Biopharma secures $53 mln financing from CRG
Monday, 17 Jul 2017 07:30am EDT 

July 17 (Reuters) - Strongbridge Biopharma Plc -:Strongbridge Biopharma Plc secures $53 million financing from crg.Strongbridge Biopharma- entered into $50 million senior credit facility with crg lp to retire its existing debt facility and provide additional capital for co.Strongbridge Biopharma Plc - strongbridge initially borrowed $40 million under term loan agreement.Strongbridge Biopharma Plc - concurrent with the first tranche, crg purchased $3 million of company's ordinary shares at a price of $6.98 per share.Strongbridge Biopharma Plc - term loan agreement has a six-year term with three years of interest-only payments.Strongbridge Biopharma Plc - co initially borrowed $40 million under term loan agreement and has option to borrow an additional $10 million.  Full Article

Strongbridge Biopharma Plc posts Q1 loss per share $0.83
Tuesday, 16 May 2017 07:30am EDT 

May 16 (Reuters) - Strongbridge Biopharma Plc :Strongbridge Biopharma Plc provides corporate update and reports first quarter 2017 financial results.Q1 loss per share $0.83.Q1 earnings per share view $-0.49 -- Thomson Reuters I/B/E/S.Strongbridge Biopharma Plc - continues to believe its existing financial resources are sufficient to fund planned operations into 2019.  Full Article

Strongbridge Biopharma files for mixed shelf offering of up to $150 mln
Friday, 28 Apr 2017 05:21pm EDT 

April 28 (Reuters) - Strongbridge Biopharma Plc -:Strongbridge Biopharma Plc files for mixed shelf offering of up to $150 million - sec filing.  Full Article

Strongbridge Biopharma Plc phase 3 sonics study more than 80 pct enrolled
Monday, 27 Mar 2017 07:30am EDT 

Strongbridge Biopharma Plc : Strongbridge Biopharma Plc provides corporate update and reports full-year 2016 financial results . Strongbridge Biopharma Plc - phase 3 sonics study is now more than 80 percent enrolled and we remain on track to fully enroll study during Q2 . Strongbridge Biopharma Plc - on schedule to commence enrollment in logics, supportive phase 3 study for COR-003, in middle of this year .Strongbridge Biopharma Plc - COR-003 phase 3 clinical development program remains on track.  Full Article

BRIEF-Strongbridge To Host Conference Call On March 12 To Announce Fourth Quarter And Year-End 2017 Results

* STRONGBRIDGE BIOPHARMA PLC TO HOST CONFERENCE CALL ON MARCH 12, 2018 TO ANNOUNCE FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)